Novo Nordisk Spins Off Parkinson's Cell Therapy to Cellular Intelligence

Novo Nordisks Parkinsons cell therapy, STEM-PD, has been acquired by Boston startup Cellular Intelligence. This AI-driven company uses advanced technology to overcome challenges in cell therapies, such as scaling up production and reducing costs. STEM-PD, which replaces lost brain cells with lab-grown dopamine neurons, has FDA fast track status and is moving forward with a phase two trial. Novo Nordisk, which shut down its cell therapy unit last year, has taken an equity stake in Cellular Intelligence, marking the end of its cell therapy portfolio. Cellular Intelligence, with over $60 million in funding, has six other early-stage projects in the works, potentially revolutionizing Parkinsons treatments using smart technology. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/0bc6786d30cec098